+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 65 Pages
  • July 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5137273
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

Summary

According to the recently published report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020'; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 16 molecules.

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).

The report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020' outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 5, 6, 3 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR) and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
  • Report Coverage

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
  • Alteogen Inc
  • Amgen Inc
  • Cinnagen Co
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Sam Chun Dang Pharm Co Ltd
  • Samsung Bioepis Co Ltd

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

aflibercept biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products

Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
  • Featured News & Press Releases

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Alteogen Inc, H2 2020
  • Pipeline by Amgen Inc, H2 2020
  • Pipeline by Cinnagen Co, H2 2020
  • Pipeline by Clover Biopharmaceuticals, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alteogen Inc
  • Amgen Inc
  • Cinnagen Co
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • CSL Ltd
  • Formycon AG
  • Gene Techno Science Co Ltd
  • Huons Global Co Ltd
  • Luye Pharma Group Ltd
  • Momenta Pharmaceuticals Inc
  • PharmAbcine Inc
  • Regeneron Pharmaceuticals Inc
  • Sam Chun Dang Pharm Co Ltd
  • Samsung Bioepis Co Ltd